Date of release March 2024 - M18 (WG3)

Working group of reference:

WG3. Coordination of in vitro-to-in vivo translation of One Health leads and candidates. (Challenge 3) Objectives. Promoting and strengthening of innovative technologies required in the translation of leads and candidates from animal to humans and vice versa to ensure the progression of qualified leads and candidates to the end of the pre-clinical phase and de-risk studies in clinical phase 1. This is restricted to advanced leads and candidate. 

T3.2 Coordination of imaging and target engagement studies. The EU RTD platforms and centres (EMBL, ESFR, OPENSCREEN) will be available to collaborate with the Action and accept PhD students for projects and experiments. (D3.2).

Deliverable 10. Report on imaging and target engagement studies

COST
What is COST?

COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks. The COST ACTIONS help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation.

OneHealthdrugs CA21111
Title:

One Health drugs against parasitic vector borne diseases in Europe and beyond

Acronym:

OneHealthdrugs

Start date of the Action:

24/10/2022

End date of the Action:

23/10/2026

CSO approval date:

27/05/2022

Memorandum of Understanding (MoU)

Download file

Contact Points
Chair:

Maria Paola Costi

Vice-Chair:

Anabela Cordeiro da Silva

COST staff

Scientific Officer:
Lucia Forzi
Administrative Officer:
Nathalie Warenghien

Administrative Team

Maria Cristina Notarsanto
Maria Esposito and Laura Leonardi